(Q51352197)

4 April 2018

title

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma (English)

1 reference

4 April 2018

1 reference

Rocío García-Carbonero

3

1 reference

4 April 2018

author name string

Fernando Rivera

1

1 reference

4 April 2018

Cristina Grávalos

2

1 reference

4 April 2018

SEOM (Spanish Society of Clinical Oncology)

4

1 reference

4 April 2018

publication date

1 July 2012

1 reference

4 April 2018

Clinical and Translational Oncology

published in

1 reference

4 April 2018

volume

14

1 reference

4 April 2018

issue

7

1 reference

4 April 2018

page(s)

528-535

1 reference

4 April 2018

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Epidemiology of upper gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Chemotherapy for gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0836-9

Recommendations on current approach to gastric cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22721798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22721798

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12094-012-0836-9

1 reference

4 April 2018

1 reference

4 April 2018